A meta-analysis of inositol for depression and anxiety disorders

Tomohiko Mukai, Taro Kishi, Yuki Matsuda, Nakao Iwata

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective This study is a meta-analysis of inositol as a treatment for depression and anxiety disorders. Methods PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients. Results Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (n = 242) were identified. Four RCTs in anxiety disorders (two obsessive-compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (n = 70) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation (all-cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (p = 0.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (p = 0.07). Inositol marginally caused gastrointestinal upset compared with placebo (p = 0.06). Conclusions Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta-analysis.

Original languageEnglish
Pages (from-to)55-63
Number of pages9
JournalHuman Psychopharmacology
Volume29
Issue number1
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Inositol
Anxiety Disorders
Meta-Analysis
Depression
Placebos
Randomized Controlled Trials
Major Depressive Disorder
Bipolar Disorder
Panic Disorder
Obsessive-Compulsive Disorder
Post-Traumatic Stress Disorders
PubMed
Libraries
Psychiatry
Anxiety
Databases
Premenstrual Dysphoric Disorder

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Mukai, Tomohiko ; Kishi, Taro ; Matsuda, Yuki ; Iwata, Nakao. / A meta-analysis of inositol for depression and anxiety disorders. In: Human Psychopharmacology. 2014 ; Vol. 29, No. 1. pp. 55-63.
@article{c520d4162d2e400a9cd17d6cf356cb81,
title = "A meta-analysis of inositol for depression and anxiety disorders",
abstract = "Objective This study is a meta-analysis of inositol as a treatment for depression and anxiety disorders. Methods PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients. Results Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (n = 242) were identified. Four RCTs in anxiety disorders (two obsessive-compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (n = 70) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation (all-cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (p = 0.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (p = 0.07). Inositol marginally caused gastrointestinal upset compared with placebo (p = 0.06). Conclusions Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta-analysis.",
author = "Tomohiko Mukai and Taro Kishi and Yuki Matsuda and Nakao Iwata",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/hup.2369",
language = "English",
volume = "29",
pages = "55--63",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

A meta-analysis of inositol for depression and anxiety disorders. / Mukai, Tomohiko; Kishi, Taro; Matsuda, Yuki; Iwata, Nakao.

In: Human Psychopharmacology, Vol. 29, No. 1, 01.01.2014, p. 55-63.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A meta-analysis of inositol for depression and anxiety disorders

AU - Mukai, Tomohiko

AU - Kishi, Taro

AU - Matsuda, Yuki

AU - Iwata, Nakao

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective This study is a meta-analysis of inositol as a treatment for depression and anxiety disorders. Methods PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients. Results Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (n = 242) were identified. Four RCTs in anxiety disorders (two obsessive-compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (n = 70) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation (all-cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (p = 0.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (p = 0.07). Inositol marginally caused gastrointestinal upset compared with placebo (p = 0.06). Conclusions Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta-analysis.

AB - Objective This study is a meta-analysis of inositol as a treatment for depression and anxiety disorders. Methods PubMed, Cochrane Library database, and PsycINFO were searched up to 14 August 2013. A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs) were conducted comparing inositol for depressed or anxiety disorder patients. Results Seven RCTs in depression (two bipolar depression studies, one bipolar depression and major depressive disorder (MDD) study, two MDD studies, and two premenstrual dysphoric disorder (PMDD) studies) (n = 242) were identified. Four RCTs in anxiety disorders (two obsessive-compulsive disorder studies, one panic disorder study, and one posttraumatic stress disorder study) (n = 70) were also identified. There were no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms and discontinuation (all-cause, side effects, and worsening psychiatric symptoms). However, inositol had marginally more responders in depression than placebo (p = 0.06), and inositol showed a trend towards superior efficacy for depressive symptoms in patients with PMDD (p = 0.07). Inositol marginally caused gastrointestinal upset compared with placebo (p = 0.06). Conclusions Our results suggest that inositol may be beneficial for depressed patients, especially those with PMDD. The main limitation of this report is that a small number of studies were included in this meta-analysis.

UR - http://www.scopus.com/inward/record.url?scp=84892579863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892579863&partnerID=8YFLogxK

U2 - 10.1002/hup.2369

DO - 10.1002/hup.2369

M3 - Article

C2 - 24424706

AN - SCOPUS:84892579863

VL - 29

SP - 55

EP - 63

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -